Literature DB >> 26190718

Interferon therapy following treatment of recurrent hepatocellular carcinoma in an 83-year-old man with hepatitis C virus-related liver cirrhosis.

Yoshikuni Kudo1,2, Hideo Terao3, Hiroaki Takeuchi4, Kenji Zeze4, Hisanori Kawasaki5, Masaaki Kodama3, Kazunari Murakami6, Toshio Fujioka6.   

Abstract

A sustained virological response and improvement of liver function were achieved by low-dose interferon (IFN) therapy following curative treatment of initial and recurrent hepatocellular carcinoma (HCC) in an 83-year-old man with hepatitis C virus (HCV)-related liver cirrhosis (CLC). Although a fourth HCC episode recurred 16 months after IFN therapy, it was successfully treated. The patient is still alive 6 years and 7 months after diagnosis of the initial HCC and has been in a tumor-free state for 19 months following treatment of the last HCC. The results of this case suggest that, given sufficient consideration of adverse effects, IFN therapy for HCV and repeated local treatment for HCC contribute to improving the prognosis even in the case of a CLC patient over 80 years of age whose condition is complicated by recurrent HCC.

Entities:  

Keywords:  Elderly; Hepatitis C virus; Hepatocellular carcinoma; Interferon therapy; Liver cirrhosis

Year:  2011        PMID: 26190718     DOI: 10.1007/s12328-011-0204-2

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  23 in total

1.  Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial.

Authors:  S Kubo; S Nishiguchi; K Hirohashi; H Tanaka; T Shuto; O Yamazaki; S Shiomi; A Tamori; H Oka; S Igawa; T Kuroki; H Kinoshita
Journal:  Ann Intern Med       Date:  2001-05-15       Impact factor: 25.391

2.  Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.

Authors:  Akiko Makiyama; Yoshito Itoh; Akinori Kasahara; Yasuharu Imai; Sumio Kawata; Kentaro Yoshioka; Hirohito Tsubouchi; Kendo Kiyosawa; Shinichi Kakumu; Kiwamu Okita; Norio Hayashi; Takeshi Okanoue
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

3.  Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?

Authors:  Naoki Hiramatsu; Tsugiko Oze; Natsuko Tsuda; Nao Kurashige; Keisuke Koga; Takashi Toyama; Masakazu Yasumaru; Tatsuya Kanto; Tetsuo Takehara; Akinori Kasahara; Michio Kato; Harumasa Yoshihara; Kazuhiro Katayama; Taizo Hijioka; Hideki Hagiwara; Shinji Kubota; Masahide Oshita; Yoshimichi Haruna; Eiji Mita; Kunio Suzuki; Kazunobu Ishibashi; Norio Hayashi
Journal:  Hepatol Res       Date:  2006-05-04       Impact factor: 4.288

4.  Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma.

Authors:  M F Chen; L B Jeng; W C Lee; T C Chen
Journal:  Surgery       Date:  1998-05       Impact factor: 3.982

5.  Efficacy of interferon therapy in elderly patients with chronic hepatitis C.

Authors:  Rikako Koyama; Yasuji Arase; Kenji Ikeda; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Masahiro Kobayashi; Norio Akuta; Takashi Someya; Tetsuya Hosaka; Hitomi Sezaki; Mariko Kobayashi; Hiromitsu Kumada
Journal:  Intervirology       Date:  2006       Impact factor: 1.763

Review 6.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.

Authors:  Miharu Hirakawa; Kenji Ikeda; Yasuji Arase; Yusuke Kawamura; Hiromi Yatsuji; Tetsuya Hosaka; Hitomi Sezaki; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Hiromitsu Kumada
Journal:  Intern Med       Date:  2008-10-01       Impact factor: 1.271

8.  Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.

Authors:  Yasuji Arase; Fumitaka Suzuki; Yoshiyuki Suzuki; Norio Akuta; Yusuke Kawamura; Masahiro Kobayashi; Tetsuya Hosaka; Hitomi Sezaki; Hiromi Yatsuji; Mariko Kobayashi; Kenji Ikeda; Hiromitsu Kumada
Journal:  Intern Med       Date:  2007-11-16       Impact factor: 1.271

9.  Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma.

Authors:  K Ikeda; S Saitoh; A Tsubota; Y Arase; K Chayama; H Kumada; G Watanabe; M Tsurumaru
Journal:  Cancer       Date:  1993-01-01       Impact factor: 6.860

10.  Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors:  S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.